MONASH University researchers have discovered a molecular biomarker in triple negative breast cancer (TNBC) tumours that could indicate when beta blockers could play a role in "switching off" tumor progression.
Stress hormones can speed up the spread of cancer, and beta blockers - a class of medication used to block the effects of stress hormones - have already been identified as a potential therapeutic option for halting cancer progression in TNBC patients.
Investigators have now discovered the genetic mechanism behind the effect.
"TNBC is an aggressive cancer which can be especially challenging to treat, and identifying new treatment pathways is important," said lead author Terrance Lam, calling for further studies.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Aug 25
